Topline
A recent study published in The Lancet on Thursday revealed that managing the early stages of medication abortion care at home later in pregnancy is not only safe but also reduces the time spent in the hospital. This research could potentially enhance access to abortion procedures, especially as reproductive rights continue to be a focal point in the 2024 election.
Key Facts
According to the Centers for Disease Control and Prevention, almost all abortions in the United States are performed at or before 13 weeks of pregnancy (the first trimester). Clinical guidelines typically recommend that abortions after the 12-week mark be conducted exclusively in clinical settings to ensure patient observation.
Medication abortions involve the use of two types of pills—mifepristone, which blocks a hormone necessary for pregnancy, and misoprostol, which induces contractions in the womb. For abortions after 12 weeks, patients are usually given mifepristone in a clinic and return a day or two later to receive misoprostol, often requiring an overnight stay in the hospital.
Based on a randomized controlled trial involving 435 women having a medical abortion between 12 and 22 weeks, researchers in Sweden found that starting misoprostol at home instead of in the hospital was as safe and effective. Women managing the early stages of care at home spent less time in the hospital.
Among pregnant individuals starting misoprostol at home and returning to clinics for further doses (multiple doses are usually needed), 71% spent fewer than nine hours in the hospital, compared to 46% in the hospital treatment group, as shown in the peer-reviewed study.
There were no significant differences in reported pain, side effects, or rates of unplanned hospital admissions between the two groups. A follow-up survey revealed that 78% of the home group preferred their treatment option compared to only 49% in the hospital group.
Dr. Johanna Rydelius, a gynecologist at Sahlgrenska University Hospital and researcher at the University of Gothenburg and one of the study’s authors, stated that these findings provide a safe alternative to a practice that many women find stressful and isolating. This new approach could offer women more autonomy during a vulnerable time.
Crucial Quote
“Increasing access to abortion later in pregnancy is a crucial component of the struggle for reproductive autonomy,” said researchers Heidi Moseson and Caitlin Gerdts from Ibis Reproductive Health in a comment piece published in The Lancet. They emphasized the strong preference for at-home misoprostol administration among participants in the study and suggested that reforming guidance for a less clinically supervised model of medical abortion care could improve access.
Why Do Current Guidelines Recommend Facility-Based Medication Abortions After 12 Weeks?
The current guidelines recommend facility-based medication abortions after 12 weeks due to the increased risk of complications in later stages of pregnancy, which may necessitate additional care. However, the requirement to administer medications in clinical settings is primarily driven by the lack of data on alternative care models, limiting access to abortion care after 12 weeks.
Key Background
Since the Supreme Court overturned Roe v. Wade in 2022, many states in the U.S. have imposed strict restrictions on abortion access. Abortion is now banned from conception in 14 states and from six weeks in four states, with the future of abortion uncertain in other states due to legal challenges. The polarizing debate around reproductive healthcare has become a major issue in the upcoming presidential election, with both Democrats and Republicans using it as a divisive topic.
Big Number
In 2021, there were a total of 625,978 legal induced abortions in the U.S., according to the CDC. The majority of these, 93.5%, occurred at or before 13 weeks of pregnancy.
Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.